Dyadic signs development and commercialization deal with BRIG BIO

Dyadic Applied BioSolutions and BRIG BIO announced the signing of a Development and Commercialization Agreement to jointly develop and commercialize recombinant bovine alpha-lactalbumin. Together, the companies aim to accelerate commercialization timelines, support commercially viable production, enhance market affordability, and expand global access to sustainable proteins with comparable functional properties to traditional dairy proteins. Under the terms of the agreement, BRIG BIO will fully fund the development program and receive a global commercial license to Dyadic’s production strains capable of producing alpha-lac developed in the Dapibus fungal expression system, and Dyadic will receive access and milestone payments and long-term shared revenue participation tied to commercial sales in addition to co-marketing and sales rights.